



# Enantioselective Total Synthesis of Hyperforin

## Citation

Sparling, Brian A., David C. Moebius, and Matthew D. Shair. 2013. Enantioselective Total Synthesis of Hyperforin. *Journal of the American Chemical Society* 135, no. 2: 644–647.

## Published Version

doi:10.1021/ja312150d

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:12563735>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Communication

## Enantioselective Total Synthesis of Hyperforin

Brian Andrew Sparling, David C. Moebius, and Matthew D. Shair

*J. Am. Chem. Soc.*, **Just Accepted Manuscript** • DOI: 10.1021/ja312150d • Publication Date (Web): 28 Dec 2012

Downloaded from <http://pubs.acs.org> on December 28, 2012

### Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications  
High quality. High impact.

# Enantioselective Total Synthesis of Hyperforin

Brian A. Sparling, David C. Moebius, Matthew D. Shair\*

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States


## Supporting Information Placeholder

**ABSTRACT:** A modular, 18-step total synthesis of hyperforin is described. The natural product was quickly accessed using latent symmetry elements, whereby a group-selective, Lewis acid-catalyzed epoxide-opening cascade cyclization was used to furnish the bicyclo[3.3.1]nonane core and set two key quaternary stereocenters.

Hyperforin (**1**)<sup>1,2</sup> was first isolated in 1971 from St. John's Wort (*Hypericum perforatum* L.) and is now considered to be the constituent of the medicinal herb responsible for its antidepressant activity.<sup>3,4</sup> Hyperforin blocks the reuptake of a variety of neurotransmitters through a unique mechanism of action, possibly by selectively activating TRPC6 (classical transient receptor potential protein).<sup>5</sup> TRPC6 activation leads to a cellular influx of Na<sup>+</sup> and Ca<sup>2+</sup>, diminishing membrane electrochemical gradient (thus indirectly inhibiting neuronal neurotransmitter reuptake) and triggering cell differentiation. As a selective activator of TRPC6, hyperforin is a powerful probe of TRPC6 biology, a critical lead for the treatment of depression and possibly other human diseases. However, the therapeutic potential of hyperforin is severely handicapped by its poor water solubility, facile oxidative degradation upon exposure to light and air,<sup>6</sup> and potent activation of pregnane X receptor,<sup>7</sup> leading to increased expression of many genes involved in xenobiotic metabolism. Access to a wide variety of hyperforin analogs is critical for mitigating these shortcomings while maintaining TRPC6 activation. While limited semisynthetic manipulation of isolated hyperforin is feasible,<sup>8</sup> total synthesis is the only possible means of obtaining diverse hyperforin analogs.

Structurally, hyperforin is one of over 200 polycyclic polyprenylated acylphloroglucinol (PPAP) natural products.<sup>9</sup> Many PPAPs are characterized by a highly oxidized bicyclo[3.3.1]nonane core densely substituted with terpenoid side chains. Widespread interest in their bioactivity and structural complexity has culminated in the total syntheses of several PPAPs.<sup>10</sup> While these PPAPs contain a geminal dimethyl group at the C8 position (hyperforin numbering), differential substitution at the hyperforin C8 position renders these otherwise effective strategies inapplicable toward hyperforin total synthesis. Numerous approaches toward hyperforin<sup>11</sup> have only resulted in one total synthesis of *ent*-hyperforin, accomplished by the Shibasaki group in 2010.<sup>12</sup> Given the considerable length of this route (51 steps from propargyl bromide), we set out to devise a new enantioselective approach that would not only incorporate elements of modularity but also exploit latent symmetry. A practical total synthesis would enable the first full SAR study of hyperforin.


## Scheme 1. (A) Synthesis Strategy for Hyperforin (**1**), (B) Comparison of This Work to Hyperforin Biosynthesis.



Our strategy for the construction of hyperforin is shown in Scheme 1. The synthesis can be deconstructed into the stepwise fusion of six easily obtainable chemicals (Scheme 1a). We postulated that **1** would be accessible from alcohol **2** through bridgehead acylation at C1 and prenylations at C3 and C7. We would access key intermediate **2** from cyclohexadiene **3** via a group-selective, Lewis acid-mediated epoxide-opening cyclization. Cyclohexadiene **3** would be synthesized in two steps through the regioselective coupling of 1,5-dimethoxy-1,4-cyclohexadiene **4** with prenyl chloride **5** and known epoxygeranyl bromide **6**.<sup>13</sup>

In developing our hyperforin synthesis, we drew inspiration from its proposed biosynthesis<sup>14</sup> (Scheme 1b). In nature, hyperforin is formed from alkylation of a nucleophilic, polyketide-derived acylphloroglucinol with geranyl pyrophosphate. Stereochemical fidelity over the course of this coupling in the biosynthesis is governed by enzyme catalysis.

### Scheme 2. Transition-State Analysis of the Cyclization of **3**.



We envisioned utilizing a similar bond disconnection in the key cyclization of our synthesis, specifically one involving a geraniol-derived fragment. While unable to exploit enzyme-driven stereoselection, we postulated that an epoxide functionality strategically placed in the geraniol fragment would be an effective means of relaying stereochemical information to the C1, C5, and C8 carbon centers, when employed in concert with a truncated, symmetric cyclohexadiene ring.


An analysis of the cyclization of **3** is depicted in Scheme 2. Owing to the symmetry of compound **3**, the quaternary carbon at C5 is prostereogenic, and the two methyl enol ethers are diastereotopic. Exposure of **3** to Lewis acid activates the epoxide for nucleophilic attack. While either methyl enol ether may engage this activated epoxide, transition state **TS-1** is favored to yield **7** over its diastereomeric transition state **TS-2**, which must adopt a boat-like conformation containing two severe eclipsing interactions in forming **8**. Additionally, a 6-(*enolendo*)-tet cyclization should be favored over a 5-(*enolendo*)-tet cyclization due to geometric constraints of the substrate.<sup>15</sup> The contributions of these factors culminate **Scheme 3. Total Synthesis of Hyperforin (1).**<sup>a</sup>

in: (1) the formation of the hyperforin bicyclo[3.3.1]nonane skeleton; (2) the introduction of stereochemistry at the C5 quaternary position; and (3) the creation of a stereogenic quaternary center at C8.

Our synthesis of hyperforin is depicted in Scheme 3. Oxymercuration followed by reductive workup of epoxygeranyl bromide **6** and subsequent TESCl-mediated silylation gave **9**. Over the course of the synthesis, it became apparent that formal silanolysis of the olefin present in **6** was indispensable. Deprotonation of cyclohexadiene **4** with *t*-BuLi, treatment with freshly prepared BaI<sub>2</sub>,<sup>16</sup> and alkylation with prenyl chloride **7** yielded diene **11**. In the absence of BaI<sub>2</sub>, non-regioselective prenylation across the pentadienyl anion took place. Coupling of **9** with the anion generated from diene **11** and *s*-BuLi gave cyclization precursor **12**.

Gratifyingly, exposure of **12** to TMSOTf and 2,6-lutidine gave the ketal **13** in 79% yield as the only isolated product. As previously mentioned, the stereochemistry of two key quaternary centers were established as a result of this transformation: at the previously prostereogenic C5 carbon, and at the C8 position. Aside from the construction of the bicyclo[3.3.1]nonane framework, the formation of a cyclic methyl ketal was an unexpected yet fortuitous outcome to this reaction, safeguarding the C7 carbinol during the subsequent allylic oxidation step. The efficiency of this approach was demonstrated by our ability to easily prepare 60 grams of **13**.

After extensive optimization, allylic oxidation of **13** was accomplished using TBHP, PhI(O<sub>2</sub>CCF<sub>3</sub>)<sub>2</sub>, and O<sub>2</sub><sup>17</sup> to afford vinylogous ester **14**.<sup>18</sup> This was an exceptionally challenging transformation given the four allylic sites present in **13** and the steric environment surrounding the desired



<sup>a</sup> Conditions: (a) Hg(OAc)<sub>2</sub>, Me<sub>2</sub>CO/H<sub>2</sub>O; NaOH, 0 °C; NaBH<sub>4</sub>, 0 °C, 91% (b) TESCl, imid, DMF, 97%; (c) *t*-BuLi, THF, -78 °C; BaI<sub>2</sub>, -78 °C; **5**, -78 to -5 °C, 85%; (d) **11**, *s*-BuLi, THF, -78 to -30 °C; **9**, -78 to -40 °C, 85%; (e) TMSOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 79%; (f) PhI(O<sub>2</sub>CCF<sub>3</sub>)<sub>2</sub>, TBHP, Cs<sub>2</sub>CO<sub>3</sub>, 4 Å MS, EtOAc, O<sub>2</sub>, -78 to 0 °C, 44%; (g) BrBMe<sub>2</sub>, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -95 °C; sat. aq. NaHCO<sub>3</sub>, 57%; (h) LiTMP, THF, -78 to 0 °C, 97%; (i) ClC(S)OC<sub>6</sub>F<sub>5</sub>, *N*-hydroxysuccinimide, pyr, PhMe, 80 °C, 82%; (j) allyl-SnBu<sub>3</sub>, BEt<sub>3</sub>, PhH, air, 72%; (k) **17**, 2-methyl-2-butene, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 86%; (l) LiTMP, TMSCl, THF, -78 to 0 °C, 90%; (m) LiTMP, THF, -78 to 0 °C; *i*-PrC(O)CN, -78 to -30 °C, 49%; (n) *p*-TsOH·H<sub>2</sub>O, PhMe, HOAc, 2-methyl-2-butene, μwave, 100 °C, 65%; (o) LDA, THF, -78 °C; Li(2-Th)CuCN, -78 to -40 °C; prenyl bromide, -78 to -30 °C, 98%; (p) LiCl, DMSO, 120 °C, 55%.

oxidation site. Hydrolysis of the ketal present in **14** to yield alcohol **15** was performed in two steps: treatment of **14** with BrBMe<sub>2</sub><sup>19</sup> followed by LiTMP-mediated methanol extrusion from the intermediate hemiketal. It was crucial to maintain the temperature of the BrBMe<sub>2</sub>-mediated hydrolysis below –90 °C; above this temperature, elimination of the triethylsilyl ether was observed.

After surveying a variety of methods to install the C7 prenyl group from **15**, we pursued a radical Keck allylation approach.<sup>20</sup> A radical precursor, thionocarbonate **16**, was generated from the reaction of alcohol **15** with ClC(S)OC<sub>6</sub>F<sub>5</sub>.<sup>21</sup> Using BEt<sub>3</sub>/air as an initiator, radical allylation of **16** with allyl–SnBu<sub>3</sub> afforded a product containing a C7 allyl group as a single diastereomer. Employing more reactive radical precursor functionality or either photochemical or thermal radical generation conditions gave inferior results for this coupling reaction. An ensuing cross-metathesis with 2-methyl-2-butene catalyzed by Hoveyda–Grubbs 2<sup>nd</sup> generation catalyst **17**<sup>22</sup> afforded **18** containing the requisite C7 prenyl moiety.

After silylation at the C3 position, sequential bridgehead deprotonation-acylation using LiTMP and *i*-PrC(O)CN<sup>10n</sup> yielded ketone **19**. This direct, one-step bridgehead acylation is noteworthy given that previously reported instances of PPAP bridgehead acylation at the C1 position require multiple steps involving a bridgehead iodide intermediate.<sup>10b,d,1</sup> One-pot desilylation and elimination to give **20** was accomplished through microwave irradiation of **19** with *p*-TsOH·H<sub>2</sub>O. The final C3 prenyl group was installed utilizing a precedented sequence<sup>23</sup> to afford hyperforin methyl ether **21**.<sup>24</sup> (1) deprotonation of **20** with LDA, (2) transmetalation with Li(2-Th)CuCN,<sup>25</sup> and (3) trapping with prenyl bromide. Finally, hyperforin (**1**) was revealed by heating a DMSO solution of **21** with LiCl.

In summary, we report an enantioselective total synthesis of hyperforin. The synthesis is 18 steps at its longest sequence, starting from geraniol. This approach is also highly scalable; to date, we have prepared over 40 mg of hyperforin. Latent symmetry elements were utilized to quickly access the hyperforin bicyclo[3.3.1]nonane core and to set two key quaternary stereocenters, specifically in the conversion of epoxide **12** to ketal **13**. This practical and modular route is already being exploited to create diverse hyperforin analogs, which we are using to further understand the SAR and underlying mechanisms of hyperforin biological and medicinal activity. Results from these studies will be reported in due course.

## ASSOCIATED CONTENT

**Supporting Information.** Experimental procedures, spectroscopic data, and <sup>1</sup>H and <sup>13</sup>C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

### Corresponding Author

shair@chemistry.harvard.edu

### Funding Sources

No competing financial interests have been declared. We acknowledge financial support from Chemiderm, Inc. B.A.S. acknowledges a NSF Predoctoral Fellowship.

## REFERENCES

- (a) Gurevich, A. I.; Dobrynin, V. N.; Kolosov, M. N.; Popravko, S. A.; Ryabova, I. D.; Chernov, B. K.; Derbentseva, N. A.; Aizenman, B. E.; Garagulya, A. D. *Antibiotiki* **1971**, *16*, 510-513. (b) Bystrov, N. S.; Chernov, B. K.; Dobrynin, V. N.; Kolosov, M. N. *Tetrahedron Lett.* **1975**, *16*, 2791-2794. (c) Brondz, I.; Greibokk, T.; Groth, P. A.; Aasen, A. J. *Tetrahedron Lett.* **1982**, *23*, 1299-1300. (d) Brondz, I.; Greibokk, T.; Groth, P.; Aasen, A. J. *Acta Chem. Scand. A* **1983**, *37*, 263-265.
- (2) For reviews specific to hyperforin, see: (a) Beerhues, L. *Phytochem.* **2006**, *67*, 2201-2207. (b) Medina, M. A.; Martínez-Poveda, B.; Amores-Sánchez, M. I.; Quesada, A. R. *Life Sci.* **2006**, *79*, 105-111. (c) Quiney, C.; Billard, C.; Salanoubat, C.; Fourneron, J. D.; Kolb, J. P. *Leukemia* **2006**, *20*, 1519-1525.
- (3) (a) Greeson, J. M.; Sanford, B.; Monti, D. A. *Psychopharmacol.* **2001**, *153*, 402-414. (b) Di Carlo, G.; Borrelli, F.; Ernst, E.; Izzo, A. A. *Trends Pharmacol. Sci.* **2001**, *22*, 292-297. (c) Müller, W. E. *Pharmacol. Res.* **2003**, *47*, 101-109. (d) Linde, K. *Forsch. Komplementmed.* **2009**, *16*, 146-155.
- (4) Chatterjee, S. S.; Bhattacharya, S. K.; Wonnemann, M.; Singer, A.; Müller, W. E. *Life Sci.* **1998**, *63*, 499-510. Also, see *Pharmacopsychiatry* **1998**, *31*, Supplementary Issue 1 and *Pharmacopsychiatry* **2001**, *34*, Supplementary Issue.
- (5) Leuner, K.; Kazanski, V.; Müller, M.; Essin, K.; Henke, B.; Gollasch, M.; Harteneck, C.; Müller, W. E. *FASEB J.* **2007**, *21*, 4101-4111.
- (6) (a) Trifunović, S.; Vajs, V.; Macura, S.; Juranic, N.; Djarmati, Z.; Jankov, R.; Milosavljević, S. *Phytochemistry* **1998**, *49*, 1305-1310. (b) Wolfender, J.-L.; Verotta, L.; Belvisi, L.; Fuzzati, N.; Hostettmann, K. *Phytochem. Anal.* **2003**, *14*, 290-297. (c) Verotta, L.; Lovaglio, E.; Sterner, O.; Appendino, G.; Bombardelli, E. *Eur. J. Org. Chem.* **2004**, 1193-1197. (d) Ang, C. Y. W.; Hu, L.; Heinze, T. M.; Cui, Y.; Freeman, J. P.; Kozak, K.; Luo, W.; Lui, F. F.; Mattia, A.; DiNovi, M. J. *Agric. Food Chem.* **2004**, *52*, 6156-6164. (e) D'Auria, M.; Emanuele, L.; Racioppi, R. *Lett. Org. Chem.* **2008**, *5*, 583-586.
- (7) (a) Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit-Singh, C. J.; Willson, T. M.; Collins, J. L.; Kliever, S. A. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 7500-7502. (b) Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-Searles, P. R.; Lambert, M. H.; Kliever, S. A.; Redinbo, M. R. *Biochemistry* **2003**, *42*, 1430-1438.
- (8) For examples, see: (a) Verotta, L.; Appendino, G.; Belloro, E.; Bianchi, F.; Sterner, O.; Lovati, M.; Bombardelli, E. *J. Nat. Prod.* **2002**, *65*, 433-438. (b) Gartner, M.; Müller, T.; Simon, J. C.; Giannis, A.; Sleeman, J. P. *ChemBioChem* **2005**, *6*, 171-177.
- (9) For reviews of PPAPs, see: (a) Ciochina, R.; Grossman, R. B. *Chem. Rev.* **2006**, *106*, 3963-3986. (b) Singh, I. P.; Sidana, J.; Bharate, S. B.; Foley, W. J. *Nat. Prod. Rep.* **2010**, *27*, 393-416. (c) Tsukano, C.; Siegel, D. R.; Danishefsky, S. J. *J. Synth. Org. Chem. Jpn.* **2010**, *68*, 592-600. (d) Njardarson, J. T. *Tetrahedron* **2011**, *67*, 7631-7666. (e) Richard, J.-A.; Pouwer, R. H.; Chen, D. Y.-K. *Angew. Chem. Int. Ed.* **2012**, *51*, 4536-4561.
- (10) (a) Kuramochi, A.; Usuda, H.; Yamatsugu, K.; Kanai, M.; Shibasaki, M. *J. Am. Chem. Soc.* **2005**, *127*, 14200-14201. (b) Siegel, D. R.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2006**, *128*, 1048-1049. (c) Rodeschini, V.; Ahmad, N. M.; Simpkins, N. S. *Org. Lett.* **2006**, *8*, 5283-5285. (d) Tsukano, C.; Siegel, D. R.; Danishefsky, S. J. *Angew. Chem. Int. Ed.* **2007**, *46*, 8840-8844. (e) Qi, J.; Porco, J. A., Jr. *J. Am. Chem. Soc.* **2007**, *129*, 12682-12683. (f) Nuhant, P.; David, M.; Pouplin, T.; Delpech, B.; Marazano, C. *Org. Lett.* **2007**, *9*, 287-289. (g) Rodeschini, V.; Simpkins, N. S.; Wilson, C. J. *Org. Chem.* **2007**, *72*, 4265-4267. (h) Ahmad, N. M.; Rodeschini, V.; Simpkins, N. S.; Ward, S. E.; Blake, A. J. *J. Org. Chem.* **2007**, *72*, 4803-4815. (i) Qi, J.; Beeler, A. B.; Zhang, Q.; Porco, J. A., Jr. *J. Am. Chem. Soc.* **2010**, *132*, 13642-13644. (j) Zhang, Q.; Mitasev, B.; Qi, J.; Porco, J. A., Jr. *J. Am. Chem. Soc.* **2010**, *132*, 14212-14215. (k) Garnsey, M. R.; Lim, D.; Yost, J. M.; Coltart, D. M. *Org. Lett.* **2010**, *12*, 5234-5237. (l) Simpkins, N. S.; Taylor, J. D.; Weller, M. D.; Hayes, C. J. *Synlett* **2010**, 639-643. (m) Simpkins, N. S.; Weller, M. D. *Tetrahedron Lett.* **2010**, *51*, 4823-4826. (n) Biber, N.; Möws, K.; Plietker, B. *Nature Chem.* **2011**, *3*, 938-942. (o) Garnsey, M. R.; Matous, J. A.; Kwiek, J. J.; Coltart, D. M. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2406-2409. (p) Uwamori, M.; Saito, A.; Nakada, M. *J. Org. Chem.* **2012**, *77*, 5098-5107.
- (11) For examples, see: (a) Kraus, G. A.; Nguyen, T. H.; Jeon, I. *Tetrahedron Lett.* **2003**, *44*, 659-661. (b) Nicolaou, K. C.; Carenzi, E. A.; Jeso, V. *Angew. Chem. Int. Ed.* **2005**, *44*, 3895-3899. (c) Coulaudouros, E. A.; Dakanali, M.; Demadis, K. D.; Vidali, V. P. *Org. Lett.* **2009**, *11*, 4430-4433. (d) Uyeda, C.; Rötheli, A. R.; Jacobsen, E. N. *Angew. Chem. Int. Ed.*

2010, 49, 9753-9756. (e) Mehta, G.; Dhanbal, T.; Bera, M. K. *Tetrahedron Lett.* **2010**, 51, 5302-5305. (f) Richard, J.-A.; Chen, D. Y.-K. *Eur. J. Org. Chem.* **2012**, 484-487, and references therein.

(12) (a) Usuda, H.; Kuramochi, A.; Kanai, M.; Shibasaki, M. *Org. Lett.* **2004**, 6, 4387-4390. (b) Shimizu, Y.; Shi, S.-L.; Usuda, H.; Kanai, M.; Shibasaki, M. *Angew. Chem. Int. Ed.* **2010**, 49, 1103-1106. (c) Shimizu, Y.; Shi, S.-L.; Usuda, H.; Kanai, M.; Shibasaki, M. *Tetrahedron* **2010**, 66, 6569-6584.

(13) **4** is synthesized from 1,3-dimethoxybenzene via Birch reduction: Piers, E.; Grierson, J. R. *J. Org. Chem.* **1977**, 42, 3755-3757. **6** is synthesized from geraniol in three steps via Sharpless epoxidation, mesylation, and bromination: (a) Hanson, R. M.; Sharpless, K. B. *J. Org. Chem.* **1986**, 51, 1922-1925. (b) Gash, R. C.; MacCorquodale, F.; Walton, J. C. *Tetrahedron* **1989**, 45, 5531-5538. See Supporting Information for more details.

(14) (a) Adam, P.; Arigoni, D.; Bacher, A.; Eisenreich, W. *J. Med. Chem.* **2002**, 45, 4786-4793. (b) Boubakir, Z.; Beuerle, T.; Liu, B.; Beerhues, L. *Phytochemistry* **2005**, 66, 51-57. (c) Klingauf, P.; Beuerle, T.; Mellenthin, A.; El-Moghazy, S. A. M.; Boubakir, Z.; Beerhues, L. *Phytochemistry* **2005**, 66, 139-145. (d) Karppinen, K.; Hokkanen, J.; Tolonen, A.; Mattila, S.; Hohtola, A. *Phytochemistry* **2007**, 68, 1038-1045.

(15) Baldwin, J. E.; Lusch, M. *J. Tetrahedron* **1982**, 38, 2939-2947.

(16) For more information on  $\text{BaI}_2$ -promoted allylation, see: (a) Yanagisawa, A.; Yasue, K.; Yamamoto, H. *Synlett* **1993**, 686-688. (b) Yanagisawa, A.; Habaue, S.; Yasue, K.; Yamamoto, H. *J. Am. Chem. Soc.* **1994**, 116, 6130-6141. (c) Corey, E. J.; Lin, S.; Luo, G. *Tetrahedron Lett.* **1997**,

38, 5771-5774. (d) Karavadhi, S.; Corey, E. J. *J. Am. Chem. Soc.* **2008**, 130, 8865-8869.

(17) For examples of similar allylic oxidation systems, see: (a) Zhao, Y.; Yeung, Y.-Y. *Org. Lett.* **2010**, 12, 2128-2131. (b) Zhao, Y.; Yim, W.-L.; Tan, C. K.; Yeung, Y.-Y. *Org. Lett.* **2011**, 13, 4308-4311.

(18) For other examples of allylic oxidation to form the C2-C4 vinylous ester, see ref. 10p and Takagi, R.; Inoue, Y.; Ohkata, K. *J. Org. Chem.* **2008**, 73, 9320-9325.

(19) (a) Guidon, Y.; Yoakim, C.; Morton, H. E. *Tetrahedron Lett.* **1983**, 24, 2969-2972. (b) Guidon, Y.; Yoakim, C.; Morton, H. E. *J. Org. Chem.* **1984**, 49, 3912-3920.

(20) (a) Keck, G. E.; Byers, J. H. *J. Org. Chem.* **1985**, 50, 5442-5444. (b) Keck, G. E.; Enholm, E. J.; Yates, J. B.; Wiley, M. R. *Tetrahedron* **1985**, 41, 4079-4094. A similar approach to C7 prenylation has been used involving a C7 iodide intermediate. For more information, see ref. 10b,d.

(21) Barton, D. H. R.; Jaszberenyi, J. C. *Tetrahedron Lett.* **1989**, 30, 2619-2622.

(22) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2000**, 122, 8168-8179.

(23) For other examples of C3 metalation-alkylation, see ref. 10d,h,l,p, and Ahmad, N. M.; Rodeschini, V.; Simpkins, N. S.; Ward, S. E.; Wilson, C. *Org. Biomol. Chem.* **2007**, 5, 1924-1934.

(24) The NMR data for this compound is consistent with that of **21** generated from treatment of isolated hyperforin with diazomethane (ref. 8a). See Supporting Information for more details.

(25) Lipshutz, B. H.; Koerner, M.; Parker, D. A. *Tetrahedron Lett.* **1987**, 28, 945-948.

